Pliant Therapeutics, Inc. Common Stock (PLRX)
Pliant Therapeutics, Inc. (PLRX) is a biotechnology company focused on developing therapies for fibrotic diseases. The company aims to create innovative treatments targeting the underlying mechanisms of fibrosis, primarily focusing on conditions such as idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders. Pliant leverages its expertise in fibrosis biology to develop small molecule therapeutics designed to modulate key pathways involved in fibrosis, with the goal of improving patient outcomes.
Company News
Pliant Therapeutics has voluntarily paused enrollment and dosing in its ongoing BEACON-IPF Phase 2b trial of bexotegrast, leading to a significant drop in its stock price. Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors who suffered significant losses.
Pliant Therapeutics' Chief Business Officer Hans Hull sold 9,900 shares of the company's common stock, valued at over $114,000. The sale was part of a nondiscretionary plan to satisfy withholding tax liabilities related to the vesting of performance-vested stock units.
Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted a loss for its first quarter on Monday. Pliant Therapeutics posted a quarterly loss of 78 cents per share, versus market expectations for a loss of 77 cents per share, according to data from Benzinga Pro. Research and development expenses rose to $37.1 million from $29.3 million for the year-ago quar...
Pliant Therapeutics, Inc. (PLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.